LCD-L34081
Document details
Summary
The introduction of the new LCD for endoscopy by capsule will impact billing processes starting in 2026. Practices will need to familiarize themselves with the related procedures and ensure that codinNew LCD for endoscopy by capsule effective 2026.
Affected codes
ICD-10-CM
Affected specialty
Gastroenterology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34081&ver=26CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA022231 · Gastroenterology
Terlivaz (terlipressin) is an injectable medication, likely to receive an assigned J-code for billing under Medicare Part B. Given its status as an orphan drug, it may qualify for pass-through payment
View alertPolicy LCD-DL38571 · Gastroenterology
The proposed LCD for Colon Capsule Endoscopy (CCE) may lead to increased compliance updates for gastroenterology practices, as it could allow for reimbursement for procedures that were previously n
View alertPolicy LCD-DL40187 · Gastroenterology
The proposed LCD for biomarker testing aims to clarify coverage criteria for metabolic dysfunction-associated conditions, potentially increasing access for necessary testing. This may lead to improved
View alertPolicy LCD-DL40272 · Gastroenterology
The proposed LCD for biomarker testing in metabolic liver disease may affect reimbursement practices by clarifying coverage policies which could lead to increased utilization of these tests. Providers
View alert